Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8018444 | 0.82 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2ANPSR1EPHX1 | |
| SCHEMBL8028322 | 0.81 | MEN1 (0.41) | ALDH1A1MEN1KMT2ANPSR1CYP1A2 | |
| SCHEMBL15106304 | 0.80 | CYP1A2 (0.43) | ALDH1A1MEN1KMT2ANPSR1CYP1A2 | |
| SCHEMBL27538081 | 0.73 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AEPHX1CASP1 | |
| SCHEMBL7299993 | 0.71 | NPC1 (0.42) | ALDH1A1MEN1KMT2AEPHX1CASP1 | |
| SCHEMBL16370006 | 0.71 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2A | |
| SCHEMBL16407804 | 0.71 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2A | |
| SCHEMBL21886493 | 0.70 | ALDH1A1 (0.52) | ALDH1A1CYP1A2 | |
| SCHEMBL26048629 | 0.70 | ALDH1A1 (0.52) | ALDH1A1CYP1A2 | |
| SCHEMBL16362626 | 0.69 | CHRM3 (0.45) | ALDH1A1MEN1KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1425009-A4 | PEPTIDE ARGINALS AND METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION | IVAX INST FOR DRUG RES LTD (HU) | 2006-10-25 | — | — | EP | disclosed |
| US-20050070480-A1 | Peptide arginals and methods for treating disseminated intravascular coagulation | IVAX DRUG RESEARCH INSTITUTE LTD. (HU) | 2005-03-31 | — | — | US | disclosed |
| EP-1425009-A2 | PEPTIDE ARGINALS AND METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION | Ivax Institute for Drug Research, Ltd. (HU) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003016273-A2 | PEPTIDE ARGINALS AND METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION | IVAX CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070480-A1 | Peptide arginals and methods for treating disseminated intravascular coagulation | ARGLU1, PLAT, SERPINC1 | ALDH1A1 4482/4885MEN1 1449/4885KMT2A 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.